載入中
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
前收盤價
US$1.22
−US$0.005 · -0.41%
盤後
US$1.2269
+US$0.0069 · +0.57%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
日內區間
目前US$1.22
52週區間
目前US$1.22
盤中時間採用ET。市場資料可能有所延遲。
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
日內區間
目前US$1.22
52週區間
目前US$1.22
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.84億 USD | 7699.4萬 USD | 23.7萬 USD | 59.6萬 USD | 139.3萬 USD |
| 銷貨成本 | 474.5萬 USD | 125.6萬 USD | — | — | — |
| 毛利 | 1.79億 USD | 7573.8萬 USD | 23.7萬 USD | 59.6萬 USD | 139.3萬 USD |
| 研究與開發 | 7371.5萬 USD | 1.04億 USD | 1.25億 USD | 9551.8萬 USD | 8572.7萬 USD |
| 銷售、一般及管理費用 | 1.59億 USD | 1.46億 USD | 6913.5萬 USD | 4362.8萬 USD | 2966.5萬 USD |
| 營業費用 | 2.33億 USD | 2.49億 USD | 1.94億 USD | 1.39億 USD | 1.15億 USD |
| 利息收入 | 1811.7萬 USD | 1960.7萬 USD | 1815.2萬 USD | 252.9萬 USD | 52.7萬 USD |
| 利息支出 | 3265.7萬 USD | 1850.4萬 USD | 831.2萬 USD | 688.2萬 USD | 374萬 USD |
| 折舊和攤銷 | 120.4萬 USD | 122.1萬 USD | 103.3萬 USD | 86.8萬 USD | 78.3萬 USD |
| 營業利益 | −5383.5萬 USD | −1.74億 USD | −1.94億 USD | −1.39億 USD | −1.14億 USD |
| 淨利 | −8578.2萬 USD | −1.75億 USD | −1.84億 USD | −1.42億 USD | −1.16億 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.89
上漲空間 382.79%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3046.94萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2177.66萬0.22%103.03億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1773.25萬0.02%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF929.54萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO639.22萬0.05%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB604.39萬0.06%108.2億 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO479.08萬0.03%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA378.16萬0.02%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
